Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.420
-0.019 (-1.30%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Cocrystal Pharma Employees
Cocrystal Pharma had 12 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,458,667
Market Cap
14.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
COCP News
- 1 day ago - Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 26 days ago - Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 - GlobeNewsWire
- 3 months ago - Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - Benzinga
- 3 months ago - Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - GlobeNewsWire
- 8 months ago - Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences - GlobeNewsWire
- 8 months ago - CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event - Accesswire
- 11 months ago - Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 11 months ago - Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza - GlobeNewsWire